Bone marrow transplantation (BMT) from siblings is the treatment of choice for severe combined immunodeficiency (SCID). The objective of this study was to evaluate the efficiency of BMT from matched unrelated donors (MUD) in congenital immunodeficiencies when a sibling donor is unavailable. Sixteen consecutive patients with SCID (n = 9) and CID (n = 7), were referred for an unrelated donor search. Acceptable donors were found for all patients. Fifteen patients received busulfan and cyclophosphamide pretransplant conditioning. One patient had an early loss of graft and was reconditioned using cyclophosphamide and total body irradiation. The graft-versus-host disease (GVHD) prophylaxis used was methylprednisolone, cyclosporin A with or without methotrexate. Neutrophil engraftment was rapid and was achieved in all patients within a mean of 15.4 days. Only 13 episodes of fever were recorded shortly after BMT. GVHD of grade II or more was apparent in 2/9 (22%) of SCID patients and in 4/7 (57%) of CID patients. Overall survival was 75% with a mean follow-up of 47.4 months (range 18-101). Six out of nine SCID patients (67%) and 6/7 (86%) of CID patients are alive and well. Eleven patients had normal humoral immunity, and cell-mediated immunity as measured by flow cytometry and mitogenic responses, was intact in all patients. Intradermal candida skin test was positive in 9/10 patients tested. We conclude that BMT from MUD results in rapid engraftment and is therefore associated with a low rate of infection contributing to the improved survival rate. Attempts to use alternative procedures have been less successful. Immunologic reconstitution following fetal thymus and/or liver transplantation is inconsistent; engraftment is achieved in less than one third of cases and a survival rate of less than 20% has been reported. 4, 5 T lymphocyte-depleted, haploidentical bone marrow, usually of parental origin, is regarded by many transplant centers as the treatment of choice when fully matched sibling donors are unavailable. Although survival for all types of SCID hovers around 50%, 6 recent preliminary experience shows a higher survival rate (70-78%) in selective SCID phenotypes mainly including T − B + SCID 7,8 and ADA deficiency 8 using this method. However, this approach has serious limitations, including prolonged time to engraftment, 9-12 and very slow B lymphocyte engraftment, which ranges in large series of patients from 40 to 70%. [9] [10] [11] [12] [13] 
marrow transplantation (BMT) using marrow from genotypically identical sibling donors remains the treatment of choice for most forms of severe combined immunodeficiency (SCID). Currently, however, only approximately 10% of infants with SCID have healthy, HLA-matched sibling bone marrow donors. 3 Attempts to use alternative procedures have been less successful. Immunologic reconstitution following fetal thymus and/or liver transplantation is inconsistent; engraftment is achieved in less than one third of cases and a survival rate of less than 20% has been reported. 4, 5 T lymphocyte-depleted, haploidentical bone marrow, usually of parental origin, is regarded by many transplant centers as the treatment of choice when fully matched sibling donors are unavailable. Although survival for all types of SCID hovers around 50%, 6 recent preliminary experience shows a higher survival rate (70-78%) in selective SCID phenotypes mainly including T − B + SCID 7, 8 and ADA deficiency 8 using this method. However, this approach has serious limitations, including prolonged time to engraftment, [9] [10] [11] [12] and very slow B lymphocyte engraftment, which ranges in large series of patients from 40 to 70%. [9] [10] [11] [12] [13] Both of these factors contribute to a high rate of infection. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Moreover, engraftment and survival rate of profound T cell immunodefiencies with residual function (CID) using this method have been poor.
Combined immunodeficiency (CID) refers to a heterogeneous group of patients, who present with severe recurrent infections and have profound but not absolute deficiencies of humoral and cell-mediated function. In recent years, the molecular defects of several CID syndromes have been identified, including lymphocyte signal transduction elements such as Zap-70, IL-2R␣, CD3, [16] [17] [18] as well as 'atypical' phenotypes arising from mutations in IL-2R␥ 19 or 'partial' ADA deficiency. 20 Experience with the application of BMT to patients with CID or T cell immunodeficiency with residual function is extremely limited. 21 Among patients transplanted for CID with T celldepleted bone marrow, engraftment rates have been poor, ranging from 14% to 30%, while short-term survival rates reached 47%, 15 and long-term survival as low as 10% have been recorded. 18 These discouraging results point to a pressing need for better transplant alternatives to ensure a full engraftment and reconstitution of immunological function, and a better long-term survival rate.
We prospectively enrolled infants and children with SCID (n = 9) or CID (n = 7) with no sibling donor into a protocol using matched unrelated donors (MUD) in an attempt to develop a better alternative to T cell-depleted haploidentical bone marrow transplantation. We conclude that BMT from MUD results in rapid engraftment and is associated with a low morbidity and improved survival rate especially in patients with combined immunodeficiency that possess residual function.
Materials and methods

Patients
Sixteen consecutive patients with SCID (n = 9), CID or T cell immunodeficiency with residual function (n = 7), diagnosed in the Division of Immunology at the Hospital for Sick Children (Toronto) between December 1989 and August 1997, who lacked histocompatible siblings or closely matched related donors, were referred to the Canadian Unrelated Bone Marrow Donor Registry for an unrelated donor search. All donors and recipients were matched by DNA genotype analysis. Data were collected until January 1999, so that all children had a minimum follow-up of 12 months after BMT.
HLA typing and donor selection
Lymphocytes from all patients were tested for HLA A, B, C and DR typing using standard serological methods. Class II histocompatibility was further analyzed by DNA hybridization with sequence-specific oligonucleotide probes. 22 Mixed lymphocyte reactions (MLR) were performed in nine out of 16 recipient-donor pairs as previously reported. 23 Patients who received a haploidentical bone marrow and/or showed a MLR reactivity of more than 20% were not included in the study.
Transplantation procedures
Patients were admitted into private HEPA-filtered rooms on the bone marrow transplant unit. Two patients (P10 and P14) were admitted to the intensive care unit due to respiratory failure caused by Pneumocystis carinii pneumonitis and one of them (P14) received his marrow transfusion in the intensive care unit. Patients were maintained under strict reverse isolation procedures throughout the admission until they were discharged from the hospital. Trimethoprim/sulfametaxozole was used for Pneumocystis carinii prophylaxis. Two patients were switched to pentamidine (4 mg/kg/dose i.v. every second week) because of possible drug-related neutropenia. Intravenous immunoglobulin (IVIG) at a dose of 600 mg/kg was infused as required to maintain IgG level above 6 g/l. Acyclovir (1500 mg/m 2 /day) was administered i.v. to five patients who received bone marrow from cytomegalovirus (CMV) seropositive donors. All blood products were CMV negative and irradiated and were infused through a 170 g filter.
Pretransplant conditioning therapy consisted of busulfan given over 4 days in doses of 4 mg/kg/day for patients over 3 years of age (n = 1), or 5 mg/kg/day for patients younger than 3 years (n = 15). This was followed by a 4-day course of cyclophosphamide (50 mg/kg/day). GVHD prophylaxis, administered to all patients from the day prior to transplant, consisted of cyclosporin A (3 mg/kg/day i.v.) or adjusted to keep a level of 150 g/l and methylprednisolone (2 mg/kg/day i.v.) for an average of 90 days. Addition of methotrexate 10 mg/m 2 on days 3, 6, 11 and 18 post BMT was added to the protocol of nine patients as previously suggested by other investigators. 24 Prednisone at various doses was continued as long as GVHD persisted. All patients were infused with 3-5 × 10 8 donor bone marrow mononuclear non-depleted cells per/kg of recipient weight. Eleven patients received GM-CSF (5.5 mg/kg/day subcutaneously) and five received G-CSF (5.0 mg/kg/day i.v.) from the day of transplant until the absolute neutrophil count was Ͼ1.0 × 10 9 /l for 3 consecutive days.
Engraftment and chimerism studies
Neutrophil engraftment was considered to have occurred on the first of 3 consecutive days in which the absolute count exceeded 500 cells per cubic millimeter. Platelet engraftment was considered to have occurred on the first day of 7 consecutive days in which the platelet count exceeded 20 000 per cubic millimeter without platelet transfusion.
Peripheral blood mononuclear cells were isolated 8-10 weeks after transplant by Ficoll-Hypaque gradient centrifugation and were analyzed for lymphocyte subpopulation engraftment using flow cytometry (Coulter Electronics, Hialeah, FL, USA). Where sex difference between donor and recipient existed, DNA was analyzed using an Yspecific probe (ZFX/ZFY) to confirm donor lymphocyte engraftment. In the absence of sex difference restriction length fragment polymorphism (RFLP) analyses were performed by studying genetic polymorphisms which are due to a variable number of tandem repeats (VNTR) or (CA) n in varying regions of the genome. Blood group phenotyping served as an additional engraftment marker.
Immune function studies
Humoral reconstitution was evaluated by measuring serum immunoglobulin levels, isohemagglutinin and specific antibody titers in response to immunization with diphtheria, tetanus toxoid and polio viruses. Evaluation of specific antibodies was done at least 6 months after cessation of IVIG treatment. Cell mediated immunity was evaluated by measuring T cell subpopulations, in vitro response to mitogens and in vivo response to heat killed intradermal Candida albicans skin test (1:100 or 1:10 dilution). All assays were performed by standard methods as previously described.
Results
Patient population and characteristics
The clinical features of the 16 patients are summarized in Table 1 . Twelve of 16 patients were males and the mean age at diagnosis was 7.4 months (range: birth-46 months). Patients were classified according to criteria of the World Health Organization. 25 Nine patients (1-9) had typical clini- cal and laboratory findings of SCID (Tables 1 and 2) . However, seven other patients (10-16) demonstrated residual T cell function and therefore were diagnosed as CID (Table  2) . Patients 14-16 were diagnosed with Omenn's syndrome, and patient 14 has been described in detail elsewhere. 26 Patients 11 and 12 were siblings and although the molecular defect of their disease remains unknown, they demonstrated the evolution of a late onset T cell immunodeficiency. Case 11 was diagnosed at the age of almost 4 years, but his sister Bone Marrow Transplantation (P12) was diagnosed immediately after birth because of the positive family history. Assessment of her immune system at the age of 3 months revealed an abnormal subset of T cells and a moderately decreased proliferative response to mitogens. Soon after, she demonstrated a gradual deterioration of T cell function. However, she was able to maintain normal levels of immunoglobulins and specific antibody production. Patient 13 had normal in vitro immune function and even a normal thymic morphology. Diagnosis of profound immunodeficiency was established only after he failed to reject a skin graft. Recently the molecular defect has been identified as a novel mutation in the common ␥ chain of the IL2 receptor. 19 Nine patients (56%) had a pulmonary infection before transplant, which is considered a bad prognostic factor, 9 and three of them were very high-risk transplants. Patient 14 received a bone marrow infusion during his admission to the intensive care unit due to severe pneumocystic carinii pneumonitis requiring prolonged mechanical ventilation. Prior to her MUD transplant patient 10 failed to engraft a haploidentical T cell-depleted BMT and reconstituted her own marrow (Table 1) . Patient 16 had a rapid engraftment with an HLA-identical MUD donor, but lost the graft within 4 weeks. He was re-conditioned with a cyclophosphamide and irradiation protocol and was re-transplanted using a harvest obtained from the same donor. The mean age at transplantation was 15.2 months (range, 2-59) ( Table 3) .
Donor selection
Acceptable donors were found for all patients within a mean of 4.7 months (range, 1-13). Thirteen patients had phenotypically identical donors while the rest had donors mismatched at one locus: A, B or C (one each). MLR was performed in nine cases. None of the MLRs demonstrated more than 7% reactivity in the direction of donor cells responding against irradiated recipient cells (Table 3) .
Hematological engraftment
Neutrophil engraftment was achieved in all patients at a mean of 15.4 days (range, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , including the patients who failed previous BMTs. Engraftment of platelets was achieved in 13 out of 16 patients with a mean of 16 days (range, 7-60). Patients 6 and 12 remained platelet dependent until they died from GVHD post BMT. Patient 7 had delayed engraftment of platelets until day 237, due to GVHD. Blood group phenotyping was switched to donor type in the nine patients who had differences in blood group before transplant (Table 4) . RFLP studies were performed in 14 cases, 8 to 10 weeks post BMT. All 14 cases demonstrated virtually 100% engraftment of donor cells, without any evidence of residual recipient cells; including the patient who had previously failed a haploidentical T cell-depleted BMT. In one other patient karyotyping analysis showed 100% female donor cells in peripheral blood.
Humoral immunity
Evaluation of humoral immune reconstitution is shown in Table 5 . Serum IgM and IgA normalized in all patients within a mean of 3.5 and 6 months, respectively, except for patient 5 whose IgA was still Ͻ0.1 g/l when he died 11 months after transplant. Eleven of 12 alive patients reached normal levels of IgG within 4 to 17 months (average 8.2 months). At the present time, patient 15 has not yet normalized her IgG levels 18 months post BMT. Eleven patients have been immunized with four doses of DPT vaccine. Levels of specific antibodies were measured 1 to 2 weeks after the second and the third immunizations, as well as at 6-month intervals. Patients began producing protective levels of specific antibodies rapidly, within 5 months of BMT. All immunized patients developed and sustained protective levels of antibodies against tetanus toxoid and polio viruses.
Cell-mediated immunity
Total lymphocyte counts and subsets of T cells, studied by flow cytometry, 1 to 2 months after BMT showed evidence of engraftment in all patients (Table 6 ). Four patients demonstrated proliferative response to mitogen stimulation within 2 months after BMT. Most recent evaluation in 10 patients showed that all have normal absolute lymphocyte + cell counts whereas patients 4, 7 and 11 have slightly lower then normal counts. Proliferative responses of T cells to stimulation with different mitogens were within normal limits in all surviving patients, with the exception of patients 15 and 16 who have not been tested yet due to continued treatment with GVHD prophylaxis. In vivo evaluation of cell-mediated immunity, assessed by intradermal candida skin test, showed positive results in nine out of 10 patients tested (Table 5 ). Patients 1, 2, 4 and 14 have experienced an uneventful varicella infection after BMT.
Infections
During hospitalization a total of 13 episodes of fever were recorded for all patients. They all occurred within a few days after BMT, while patients were severely neutropenic. In five episodes bacterial agents were recovered from blood cultures including Enterobacter cloacae, gram-negative bacilli, Pseudomonas aeruginosa and Staphylococcus coagulase negative. Blood cultures obtained from patients during the rest of the febrile episodes failed to detect bacterial, fungal or viral infection. All patients recovered after administration of antibiotic therapy.
Graft-versus-host disease
GVHD of grade II or more was clinically apparent in six patients. In the SCID population, two out of nine (22%) developed grade III GVHD and subsequently died from this complication ( Table 3 ). The mean age of transplant for SCID patients was 6.25 months (range 4.5-6.5 months). However, in the CID group four out of seven (57%) developed GVHD of grade II or more, possibly due to their advanced age (mean 26.3) as compared with SCID patients (Table 3) . GVHD was reversed in three out of four in CID patients. Patients 11 and 12 were siblings who received marrow from the same donor at the ages of 59 and 24 months, respectively. Patient 11 developed grade II GVHD that was reversed after a pulse of methylprednisolone (20 mg/kg/day) administered over 3 consecutive days. Patient 12 did not have any symptoms of GVHD for more than 2 months post BMT. She developed a full blown, three organ involvement GVHD several days after GVHD prophylaxis was switched from i.v. to equivalent doses of oral medi-cation resulting in a sharp decline in cyclosporin A serum levels. A pulse of high-dose steroids was administered but had to be discontinued due to a massive gastrointestinal bleed. She responded partially to repeated courses of antithymocyte globulin (ATG). A trial of anti-IL-2R antibody was unsuccessful and she subsequently died 7 months post BMT. Only three patients (1, 9, 15) developed mild chronic GVHD of the skin. In two cases it subsequently resolved after treatment with topical steroids. Only patient 15 still requires low doses of cyclosporin A and steroids to control her chronic GVHD.
Survival and cause of death
Seventy-five percent of patients remain alive and well 6 to 101 months post BMT (mean 47.4 months). Six out of nine (67%) SCID patients and six of seven (86%) CID patients are alive. The actuarial survival rate for our group of patients was 74% as shown in Figure 1 . Patients 5, 6, 8 and 12 developed GVHD and subsequently died 13, 2.5, 12 and 7 months post BMT, respectively (Table 3) 
Discussion
We report a series of 16 patients with SCID (n = 9) and CID (n = 7), who received an unmodified BMT from matched unrelated donors. This procedure is currently one of two preferred approaches in cases where a suitable donor could not be identified in the patient's family. Only a small number of reports, which include a relatively limited number of cases, have studied the option of MUD BMT for SCID and CID patients. 27, 28 Two main obstacles appear to be associated with using MUD transplants. First, donor availability through the bone marrow registries, is a particular concern for smaller or non-participating ethnic groups. Furthermore, there may be a waiting period until the bone marrow is harvested, shipped and finally administered to the patient. It appears that these concerns have gradually been addressed, and although they are not yet optimal, great progress has already been achieved. We have been able to identify a suitable donor through the evergrowing International Registry for all our patients, and waiting time has been reduced from months to sometimes weeks. Further improvement is likely to occur in light of massive enrollment in BMT registries, improved records of HLA determination and enhanced international communication.
The second major obstacle to declaring this mode of treatment ideal, is the consistent complication, GVHD. All our patients developed GVHD in spite of treatment with cyclosporin A and corticosteroids, with or without the addition of methotrexate. Although in most patients, this complication was transient and limited to the skin, in some it ultimately contributed directly or indirectly to patients' deaths. In two patients, switching prophylaxis to oral administration 6 to 8 weeks post BMT resulted in a sharp drop in cyclosporin A level and presumably triggered fatal GVHD. A third patient developed hepatic failure when GVHD prophylaxis was reduced, while the fourth patient developed bone marrow aplasia following a rapid reduction of immune suppression 5 to 6 months post transplantation.
These results clearly highlight the critical importance of maintaining adequate cyclosporin A levels during the first 3 months post BMT as previously suggested, 29 even if no signs of GVHD are apparent. Furthermore, frequent monitoring and strict follow-up appears extremely important when immunosuppression is being reduced, even months after bone marrow transplantation. Such follow-up cannot be left to unqualified medical staff and preferably should be performed by an experienced bone marrow transplantation facility.
The second therapeutic approach currently adopted by many centers throughout the world is the use of modified (depleted) haploidentical bone marrow, which is extracted from a family member. Although this approach uses an immediately available resource, it is plagued with multiple problems regardless of the method used. Engraftment is slow, exposing patients to fatal infections over long periods of time. 30, 31 Furthermore, greater than half of survivors remain with humoral immunodeficiency for years and at least 30% 6, 32 to 65% 8 never show B cell engraftment. In addition, acute and chronic GVHD remains a major concern in up to 50% of patients. 10, 33, 34 Long-term survival rates in multiple European centers using T cell-depleted bone marrow transplants appears to be below 50%, as reported in 1998. 6 Recently, more preliminary and relatively short-term experience reported by the same group suggests much improved outcome mainly in a selective group of T − B + SCID (70%), but remained fairly low for the B − T + SCID group. 7 The best results of T cell-depleted BMT for mismatched transplants were recently reported by Buckley et al. 8 This single centre experience shows that although B cell engraftment is poor, at 40%, survival rate was at 78%. Again, most patients had either ␥c deficiency or ADA deficiency. Although a group of other autosomal recessive SCIDs are mentioned, it remains unclear whether B − T + SCIDs, who appear to have a lower survival rate using this method, were included in this survey. Consistent with these results, only one of three who have not survived in our SCID series had a mutation in ␥c. Overall, these results suggest that some SCID variants such as T − B + and ADA deficiency may have a better outcome using haploidentical T cell-depleted BMT. In contrast, the experience using T cell-depleted bone marrow for CID was universally low (19-47% survival rate). 21, 35 We show here that a MUD BMT performed on patients with residual immune function such as CID and Omenn's syndrome (Rag gene normal, B + T + ) has a relatively high (85%) success rate. Further, 5/6 patients with Wiscott-Aldrich syndrome have successfully engrafted with MUD transplants in our unit (manuscript in preparation). There is no clear explanation for this major difference in the success rate between the MUD and depleted haploidentical BMT for CID transplantation. One possible explanation is the increased risk for overwhelming infection in this patient population due to pre-transplant cytoreduction, skin lesions and/or delayed engraftment and therefore increased microbial colonization and morbidity. Rapid engraftment, and therefore very low rates of infection achieved by MUD transplantation, may be the critical factor for the increased survival of these patients.
Together, these data promote the idea that adhering to one method of BMT for immunodeficiency may not lead to further significant improvement. Rather, selecting the most successful modality of therapy for the various subgroups of patients with immunndeficiency seems more plausible. Thus, patients with T − B + SCID and ADA deficiency might benefit from haploidentical depleted marrow, while patients with CID and Omenn's syndrome may be best served by a MUD transplant.
Note added in proof
Since the completion of data collection, patient 15 developed multiple exacerbations of GVHD, involving mainly the skin and liver and eventually resulting in graft failure. The patient's parents admittedly discontinued prednisone treatment against medical advice, probably contributing to this outcome. Rescue with cord blood transplantation failed and the patient died of multi-organ failure.
